Cargando…

Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice

INTRODUCTION: Omalizumab is a recombinant humanized anti-IgE monoclonal antibody, approved for patients affected by chronic spontaneous urticaria resistant to antihistamines. Although the clinical benefit of omalizumab has been established in several clinical trials, there are very little data about...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vollono, Laura, Piccolo, Arianna, Lanna, Caterina, Esposito, Maria, Bavetta, Mauro, Campione, Elena, Bianchi, Luca, Diluvio, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735630/ https://www.ncbi.nlm.nih.gov/pubmed/31564834 http://dx.doi.org/10.2147/DDDT.S214307

Ejemplares similares

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria
por: Diluvio, Laura, et al.
Publicado: (2020)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
por: García-Gómez, Elizabeth, et al.
Publicado: (2022)

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence
por: Metz, Martin, et al.
Publicado: (2020)

OMALIZUMAB IN TREATMENT-RESISTANT CHRONIC SPONTANEOUS URTICARIA
por: Godse, Kiran V
Publicado: (2011)

Profile of omalizumab in the treatment of chronic spontaneous urticaria
por: Labrador-Horrillo, Moises, et al.
Publicado: (2015)

A Case of Pincer Nail Successfully Treated with Tazarotene 0.1% Gel
por: Vollono, Laura, et al.
Publicado: (2020)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
por: Liao, Shuang-Lu, et al.
Publicado: (2021)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
por: Özdemir, Öner
Publicado: (2023)

Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome
por: Jeong, Soo Hyun, et al.
Publicado: (2022)

The Effectiveness of a New Topical Formulation Containing GSH-C4 and Hyaluronic Acid in Seborrheic Dermatitis: Preliminary Results of an Exploratory Pilot Study
por: Campione, Elena, et al.
Publicado: (2019)

Melanocytic lesion in children and adolescents: an Italian observational study
por: Lanna, Caterina, et al.
Publicado: (2020)

Omalizumab in chronic spontaneous urticaria (CSU): experience in three cases
por: Valle, Solange Oliveira Rodrigues, et al.
Publicado: (2015)

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014)

Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
por: Metz, Martin, et al.
Publicado: (2021)

Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
por: Kara, Rabia Oztas, et al.
Publicado: (2022)

Cost‐effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria
por: Denman, Sarah, et al.
Publicado: (2022)

Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China()
por: Wang, Ao, et al.
Publicado: (2022)

Dermoscopy and Reflectance Confocal Microscopy in the Diagnosis and Management of Nail Fold Squamous Cell Carcinoma
por: Mazzilli, Sara, et al.
Publicado: (2020)

Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
por: Chen, Yudi, et al.
Publicado: (2021)

Omalizumab for the Treatment of Chronic Spontaneous Urticaria: Association Between Body Mass Index and Outcome
por: Russo, Irene, et al.
Publicado: (2022)

Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria
por: Finlay, A.Y., et al.
Publicado: (2017)

Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria: a single-center experience()
por: Akdaş, Elçin, et al.
Publicado: (2023)

Latest Evidence Regarding the Effects of Photosensitive Drugs on the Skin: Pathogenetic Mechanisms and Clinical Manifestations
por: Lozzi, Flavia, et al.
Publicado: (2020)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
por: Godse, Kiran, et al.
Publicado: (2016)

Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Common Variable Immunodeficiency
por: Comberiati, Pasquale, et al.
Publicado: (2019)

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
por: Graham, Jonathan, et al.
Publicado: (2016)

Response of FcεRI‐bearing leucocytes to omalizumab in chronic spontaneous urticaria
por: Alizadeh Aghdam, Mehran, et al.
Publicado: (2020)

Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
por: Sardina, Davide Stefano, et al.
Publicado: (2021)

Omalizumab Reduces Unplanned Healthcare Interactions in Irish Patients With Chronic Spontaneous Urticaria
por: Ridge, Katie, et al.
Publicado: (2021)

The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment
por: Atayik, E., et al.
Publicado: (2022)

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
por: Casale, Thomas B., et al.
Publicado: (2023)

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab
por: Puxkandl, Viktoria, et al.
Publicado: (2023)

Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016)

Urticaria and angioedema as possible reactions of omalizumab
por: Ozbagcivan, Ozlem, et al.
Publicado: (2018)

Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life
por: Galletta, Francesca, et al.
Publicado: (2023)

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America
por: Cherrez-Ojeda, Ivan, et al.
Publicado: (2019)

Omalizumab Use in Chronic Spontaneous Urticaria during Pregnancy and a Four Years' Follow-Up: A Case Report
por: Losappio, Laura Michelina, et al.
Publicado: (2020)

A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium
por: Lapeere, H., et al.
Publicado: (2019)

274 Vasculitic Urticaria Treated with Omalizumab. Case Report
por: Ramírez Del Pozo, María Elena, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nt8iojl6c21m91jvliok96vugg